Multiple myeloma (first line) - bortezomib and thalidomide: notice of appeal

Bortezomib and Thalidomide for the first-line treatment of multiple myeloma: Notice of Appeal

NICE has received one appeal against the Final Appraisal Determination on the above technology from the following organisation:

  • Janssen-Cilag

The appeal panel will convene on 15 November 2010 to hear oral representations from the appellants.

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of places for observers is constrained by the venue, and priority will be given to members of the public who are not employed by the appellant. There are twenty five places available for this appeal hearing.

Where possible, requests to attend should be made using the form that will be available on the Institute's web site. This form will be available from 24 September 2010 only. The web site registration will allow requests to attend to be granted on a first-come, first-served basis. The registration period for this appeal will end at 5pm 8 October 2010. Further details relating to public attendance at this appeal are available on the same webpage as above.

A limited number of places at the appeal hearing will be reserved for members of the public who do not have access to the internet. These places should be applied for in writing, addressed to the Appeals Coordinator, to arrive before 5pm on 8 October 2010. Written requests to attend will also be granted on a first-come, first-served basis.

This page was last updated: 23 September 2010